 JENA, Germany, March 25, 2021 GLOBE NEWSWIRE -- InflaRx Nasdaq: IFRX, a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today financial results for the year ended December 31, 2020. 